Phase II Study Of Neoadjuvant Chemotherapy In Borderline Resectable Pancreatic Adenocarcinoma

NCT00728000 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped study withdrawn due to lack of enrollment

Conditions

Pancreatic Adenocarcinoma

Interventions

DRUG: Gemcitabine
DRUG: Oxaliplatin
DRUG: Erlotinib

Sponsor

University of Cincinnati

Collaborators

[object Object]